Search Results for "Diabetes"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Diabetes. Results 251 to 260 of 385 total matches.

Midodrine for Orthostatic Hypotension

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 1997  (Issue 1003)
syndromes including Parkinson’s disease, diabetic neuropathy, pure autonomic failure and Shy-Drager ...
Midodrine hydrochloride (ProAmatine - Roberts), an alpha1-selective adrenergic agonist, is now available for treatment of severe symptomatic orthostatic hypotension. Other treatments for this condition include other sympathomimetics, constrictive garments, erythropoietin (Epogen; Procrit) and fludrocortisone with salt (D Robertson and TL Davis, Neurology, 45 suppl 5: S26, 1995).
Med Lett Drugs Ther. 1997 Jun 20;39(1003):59-60 |  Show IntroductionHide Introduction

Cool.click: A Needle-free Device For Growth Hormone Delivery

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2001  (Issue 1095)
diabetes mellitus, most reported that injecting saline with cool.click was less painful than ...
A new needle-free system (cool.click) has been approved by the FDA for subcutaneous delivery of Saizen (recombinant somatotropin - Serono). Somatotropin is used for long-term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone. Children with growth hormone deficiency require injections daily or several times weekly for many years.
Med Lett Drugs Ther. 2001 Jan 8;43(1095):2-3 |  Show IntroductionHide Introduction

Lurasidone (Latuda) for Schizophrenia

   
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011  (Issue 1358)
. Extrapyramidal Elevated QTc Weight Drug Diabetes Symptoms Prolactin Prolongation Gain Aripiprazole ...
The FDA has approved lurasidone (Latuda - Sunovion), a new second-generation antipsychotic, for oral treatment of schizophrenia in adults.
Med Lett Drugs Ther. 2011 Feb 21;53(1358):13-4 |  Show IntroductionHide Introduction

Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive

   
The Medical Letter on Drugs and Therapeutics • Jul 08, 2013  (Issue 1420)
artery disease, heart failure, cerebrovascular disease, diabetes with end-organ damage or migraine ...
The FDA has approved Quartette (Teva), an extended-cycle combination oral contraceptive containing increasing doses of the estrogen ethinyl estradiol (EE) combined with the progestin levonorgestrel (LNG). The rationale is that a gradual increase in the EE dose may reduce unscheduled bleeding or spotting, a common adverse effect of extended-cycle oral contraceptives.
Med Lett Drugs Ther. 2013 Jul 8;55(1420):54-5 |  Show IntroductionHide Introduction

In Brief: Cardiovascular Outcomes with Bempedoic Acid (Nexletol)

   
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023  (Issue 1674)
diabetes, worsening hypoglycemia, The Medical Letter ® Vol. 65 (1674) April 17, 2023 63 metabolic ...
Since our initial review of the oral lipid-lowering adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid (Nexletol – Esperion) in 2020, cardiovascular outcomes data in statin-intolerant patients have become available.
Med Lett Drugs Ther. 2023 Apr 17;65(1674):62-3   doi:10.58347/tml.2023.1674b |  Show IntroductionHide Introduction

Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018  (Issue 1543)
such as diabetic foot and decubitus ulcer infections, human and animal bites, and necrotizing fasciitis ...
The FDA has approved delafloxacin (Baxdela – Melinta), an anionic fluoroquinolone antibiotic, for oral and parenteral treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is the first fluoroquinolone to be approved for treatment of MRSA.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):49-51 |  Show IntroductionHide Introduction

Tacrolimus FK506 Organ Transplants

   
The Medical Letter on Drugs and Therapeutics • Sep 16, 1994  (Issue 931)
), gastrointestinal disturbances (diarrhea, nausea, vomiting), hyperkalemia, hyperglycemia and new onset of diabetes ...
Tacrolimus (Prograf - Fujisawa), previously called FK506 (Medical Letter, 33:94, 1991), has been approved by the US Food and Drug Administration for primary prevention of organ rejection in patients receiving liver transplants. The drug has also been used as rescue therapy for organ graft rejection unresponsive to cyclosporine (Sandimmune) and other immunosuppressive drugs.
Med Lett Drugs Ther. 1994 Sep 16;36(931):82-3 |  Show IntroductionHide Introduction

Sildenafil: An Oral Drug for Impotence

   
The Medical Letter on Drugs and Therapeutics • May 08, 1998  (Issue 1026)
significant improvement in subgroups with cardiovascular disease, diabetes, transurethral prostatectomy ...
Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).
Med Lett Drugs Ther. 1998 May 8;40(1026):51-2 |  Show IntroductionHide Introduction

Update on Glucosamine For Osteoarthritis

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
), but exacerbation or development of diabetes has not been reported in clinical trials of oral glucosamine taken ...
Since the last Medical Letter article on glucosamine for osteoarthritis (vol.39, page 91, September 26, 1997), more data have become available. Glucosamine is available in US pharmacies and health food stores as sulfate, hydrochloride or n-acetyl salt.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):111-2 |  Show IntroductionHide Introduction

Drug-eluting Stents

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
. The risk of in-stent restenosis is increased in patients with diabetes, small vessels, long coronary ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):23-4 |  Show IntroductionHide Introduction